FMI Anti-Obesity Therapeutics Market Forecast and Segm | Page 6

Anti-Obesity Therapeutics Market
anti-obesity therapeutics market in terms of revenue and volume as the one third of the population of
North America facing the obesity and related disorders. The Western Europe is also contributed the
significant shares to the global anti-obesity therapeutics market in terms of revenue due to increasing
awareness about the obesity and related issues. The APEJ is the most lucrative market for the anti-
obesity therapeutics as the rapidly changing lifestyle and eating habits resulted in the obesity and
expected to register a moderate growth rate over a forecast period. The MEA and Latin America are at a
nascent stage of the global anti-obesity therapeutics market and anticipated to show a healthy growth in
the global anti-obesity therapeutics market over a forecast period. Overall, the global anti-obesity
therapeutics market is expected to register a significant CAGR over a forecast period.
Browse Full Report@ http://www.futuremarketinsights.com/reports/anti-obesity-therapeutics-market
Anti-Obesity Therapeutics Market: Key Players
The key players of the global anti—obesity therapeutics market are Becton, Dickinson And Company,
Boehringer Ingelheim GmbH, Bristol-Myers Squibb Pharmaceutical Ltd., Eli Lilly and Company,
GlaxoSmithKline plc., Johnson & Johnson Inc., Medtronic Inc., Merck & Co., Inc., Novartis International
AG, Novo Nordisk A/S, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA.
©2015 Future Market Insights, All Rights Reserved
6